查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587436

美國伴同性動物保健市場規模、佔有率和趨勢分析報告：按動物類型、按產品、按分銷管道、按最終用途、按國家、細分市場預測，2025-2030 年

U.S. Companion Animal Health Market Size, Share & Trends Analysis Report By Animal Type (Dogs, Cats, Equine), By Product (Vaccines, Pharmaceuticals, Supplements), By Distribution Channel, By End Use, By Country, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

美國伴同性動物保健市場的成長與趨勢：

預計2030年，美國伴同性動物保健市場規模將達到139.7億美元，2025年至2030年複合年成長率預計為9.87%。

越來越多的寵物飼主為其伴同性動物尋求更好的醫療保健服務、更健康的優質食品以及優質的美容和培訓服務，這是這個市場的主要驅動力。根據全國寵物主人調查，美國有 9,050 萬家庭擁有寵物，其中 6,900 萬家庭擁有狗。此外，高所得者約佔總支出的60%。近年來，寵物擁有量顯著成長。根據 HABRI（人類與動物關係研究計劃基金會）透露，這主要是因為寵物的存在讓人們變得更健康、更快樂。

隨著伴同性動物越來越受歡迎，人們對它們健康的擔憂也越來越多，這與寵物保險有著直接的關聯。目前，寵物保險僅佔保險業的一小部分。勃林格殷格翰動物保健公司、Chewy、Elanco、MWI 動物保健公司、Covetrus 和 PetIQ 等主要企業宣布，他們正在努力在冠狀病毒大流行期間實現更靈活的獸醫檢測。擴大遠端醫療解決方案。

新療法和伴同性動物疫苗的核准繼續為該市場提供利潤豐厚的成長機會。 COVID-19 危機進一步加速了電子商務、寵物保險、獸醫遠端醫療、照護端診斷測試和獸醫實踐數位化等持續採用趨勢。

突破性的技術進步正在迅速改變寵物健康產業。這種擴張最大限度地發揮了成長潛力。公司正在寵物健康方面採取策略性舉措，包括採用巨量資料、穿戴式技術來監測寵物健康，以及納入幹細胞療法。此外，現有企業正致力於擴大其投資組合。例如，Elanco 於 2019 年 8 月收購了拜耳公司的動物用藥品部門。

美國已經獲得了相當大的市場佔有率。該國所獲得的佔有率主要歸功於具有廣泛擴大策略的知名市場參與者的存在。此外，企業發起的研發投資增加是關鍵的潛在成長要素之一，據估計，這也是美國佔據大量佔有率的原因。

美國伴同性動物保健市場報告亮點

  • 按動物類型分類，由於寵物照護支出增加，尤其是在新興市場，狗類細分市場在 2024 年以 40.57% 的最高收益佔有率引領市場。
  • 從產品來看，由於延長寵物壽命的需求不斷成長以及研發活動的活性化，製藥業預計將在未來幾年受到歡迎。
  • 從分銷管道來看，由於寵物飼主的便利性提高，電子商務產業預計將在預測期內快速成長。
  • 按最終用途分類，醫院和診所行業以 2024 年 50.68% 的最大銷售佔有率引領市場。獸醫醫院和診所鼓勵寵物飼主尋求有效的治療，教育他們診斷和藥物對寵物健康的價值。
  • Vetiquinol SA、Zoetis、默克、Ceva Sante Animale、勃林格殷格翰有限公司、Elanco 因其產品供應和強大的區域影響力而成為一些主要的市場參與企業。
  • 公司採用各種策略來獲得競爭優勢，包括新產品開發、聯盟、併購、聯盟和地理擴張。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章美國伴同性動物保健市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 配套市場前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
    • 市場問題分析
  • 美國伴同性動物保健市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 法律規範
    • 價格分析
    • 產品平臺分析
    • 2018-2024 年美國寵物數量估計
    • COVID-19 影響分析

第4章美國伴同性動物保健市場：按動物類型的估計和趨勢分析

  • 細分儀表板
  • 美國伴同性動物保健市場：2024 年和 2030 年按動物類型分類的波動分析和市場佔有率
  • 狗
  • 貓
  • 馬
  • 其他

第5章美國伴同性動物保健市場：依產品類型估價和趨勢分析

  • 細分儀表板
  • 美國伴同性動物保健市場：2024 年和 2030 年產品變異分析和市場佔有率
  • 生物製藥
    • 疫苗
    • 其他生物製藥
  • 藥品
    • 寄生劑
    • 抗感染
    • 發炎（藥
    • 止痛藥
    • 其他
  • 補充品
  • 診斷
  • 其他

第6章美國伴同性動物保健市場：依通路估算與趨勢分析

  • 細分儀表板
  • 美國伴同性動物保健市場：2024 年和 2030 年分銷管道變化分析和市場佔有率
  • 零售
  • 電子商務
  • 醫院/診所藥房

第7章美國伴同性動物保健市場：最終用途的估計和趨勢分析

  • 細分儀表板
  • 美國伴同性動物保健市場：2024 年和 2030 年最終用途變化分析和市場佔有率
  • 醫院/診所
  • 照護現場
  • 其他

第8章 競爭格局

  • 市場參與企業分類
  • 企業市場分析/堆圖分析
  • 公司簡介
    • Merck &Co., Inc.
    • Elanco
    • Boehringer Ingelheim GmbH
    • Ceva Sante Animale
    • Zoetis
    • Virbac
    • IDEXX
    • Mars Inc.
    • Dechra Pharmaceuticals Plc（EQT）
    • Vetoquinol SA
Product Code: GVR-3-68038-960-9

U.S. Companion Animal Health Market Growth & Trends:

The U.S. companion animal health market size is estimated to reach at USD 13.97 billion in 2030 and is projected to grow at a CAGR of 9.87% from 2025 to 2030. The rising number of pet owners seeking better healthcare services, healthier quality foods, and high-end grooming and training services for their companion animals is a major driver for this market. According to theNational Pet Owners Survey, 90.5 million families in the U.S. own a pet, out of which 69.0 million own a dog. Moreover, high-income families amounted to approximately 60% of the total spending. In recent years, pet adoption has shown immense growth. This is primarily attributed to the fact that people are healthier and happier in the presence of pets, as found by the Human-Animal Bond Research Initiative Foundation (HABRI).

With the rising adoption of companion animals and growing concerns over their health, there comes a direct association with pet insurance. Presently, pet insurance accounts for a small segment in the insurance industry. The Covid-19 pandemic positively impacted the market growth in the U.S. Key players such as Boehringer Ingelheim Animal Health, Chewy, Elanco, MWI Animal Health, Covetrus, and PetIQ focused on expanding their telemedicine solutions into the market as governments relaxed governance to enable more flexible veterinary examinations during the coronavirus pandemic.

Approval of novel therapeutics and companion animal vaccines continues to present this market with lucrative growth opportunities. Ongoing trends for the adoption of e-commerce, pet insurance, veterinary telemedicine, point of care diagnostic testing, and digitalization of veterinary practices are further accelerated by the crisis of COVID-19.

Groundbreaking technological advances are rapidly transforming the pet health industry. These expansions are maximizing the potential for growth. Companies are taking strategic initiatives in pet health, such as the adoption of big data, wearable technologies to monitor pet health, and the inclusion of stem cell therapy. Moreover, established players are focusing on expanding their portfolios. For instance, Elanco acquired Bayer AG's animal health business unit in August 2019.

The U.S. captured a substantial share of the market. The share attained by this country is primarily a consequence of the presence of prominent market players undertaking extensive expansion strategies. Moreover, the increasing number of R&D investments initiated by the companies is one of the key potential growth factors presumed to be responsible for the sizeable share garnered by the U.S.

U.S. Companion Animal Health Market Report Highlights:

  • Based on animal type, the dogs segment led the market with the largest revenue share of 40.57% in 2024 due to the increasing spending on pet care, specifically in developed regions.
  • By product, the pharmaceuticals segment is expected to gain popularity in the coming years owing to the growing demand to increase pet longevity and rising R&D activities.
  • On the basis of distribution channel, the e-commerce segment is anticipated to witness rapid growth over the forecast period due to the increased convenience offered to pet owners.
  • Based on end use, the hospitals & clinics segment led the market with the largest revenue share of 50.68% in 2024. Veterinary hospitals and clinics encourage pet owners to seek out effective treatments by educating them on the value of diagnostics and medication for their pet's health.
  • Vetiquinol S.A., Zoetis, Merck, Ceva Sante Animale, Boehringer Ingelheim GmbH, and Elanco are some of the major market participants due to their product offerings and strong regional presence.
  • Companies are adopting various strategies to gain competitive advantages, such as new product development, partnerships, mergers and acquisitions, collaborations, and regional expansion.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Companion Animal Health Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising prevalence of pet diseases
      • 3.2.1.2. Growing uptake of pet insurance
      • 3.2.1.3. Increasing pet population
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of advanced treatment
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. U.S. Companion Animal Health Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
    • 3.3.3. Regulatory Framework
    • 3.3.4. Pricing Analysis
    • 3.3.5. Product Pipeline Analysis
    • 3.3.6. Estimated Number of pet popultion in U.S., 2018-2024
    • 3.3.7. COVID-19 Impact Analysis

Chapter 4. U.S. Companion Animal Health Market: Animal type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Companion Animal Health Market: Animal type Movement Analysis & Market Share, 2024 & 2030
  • 4.3. Dogs
    • 4.3.1. Dogs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Cats
    • 4.4.1. Cats Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Equine
    • 4.5.1. Equine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Companion Animal Health Market: Product Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Companion Animal Health Market: Product Movement Analysis & Market Share, 2024 & 2030
  • 5.3. Biologics
    • 5.3.1. Biologics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2. Vaccines
      • 5.3.2.1. Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 5.3.2.2. Modified/ Attenuated Live
        • 5.3.2.2.1. Modified/ Attenuated Live Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 5.3.2.3. Inactivated (Killed)
        • 5.3.2.3.1. Inactivated (Killed) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 5.3.2.4. Other Vaccines
        • 5.3.2.4.1. Other Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3. Other Biologics
      • 5.3.3.1. Other Biologics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Pharmaceuticals
    • 5.4.1. Pharmaceuticals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. Parasiticides
      • 5.4.2.1. Parasiticides Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Anti-infectives
      • 5.4.3.1. Anti-Infectives Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.4. Anti-Inflammatory
      • 5.4.4.1. Anti-Inflammatory Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.5. Analgesics
      • 5.4.5.1. Analgesics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.6. Others
      • 5.4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Supplements
    • 5.5.1. Supplements Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Diagnostics
    • 5.6.1. Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Companion Animal Health Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Companion Animal Health Market: Distribution Channel Movement Analysis & Market Share, 2024 & 2030
  • 6.3. Retail
    • 6.3.1. Retail Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. E-Commerce
    • 6.4.1. E-Commerce Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Hospital/ Clinic Pharmacies
    • 6.5.1. Hospital/ Clinic Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. U.S. Companion Animal Health Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Companion Animal Health Market: End Use Movement Analysis & Market Share, 2024 & 2030
  • 7.3. Hospitals & Clinics
    • 7.3.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Point-of-Care
    • 7.4.1. Point-of-Care Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Others
    • 7.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Company Market Position Analysis/ Heap Map Analysis
  • 8.3. Company Profiles
    • 8.3.1. Merck & Co., Inc.
      • 8.3.1.1. Participant's Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Product Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Elanco
      • 8.3.2.1. Participant's Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Boehringer Ingelheim GmbH
      • 8.3.3.1. Participant's Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Ceva Sante Animale
      • 8.3.4.1. Participant's Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Zoetis
      • 8.3.5.1. Participant's Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Virbac
      • 8.3.6.1. Participant's Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. IDEXX
      • 8.3.7.1. Participant's Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Mars Inc.
      • 8.3.8.1. Participant's Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Dechra Pharmaceuticals Plc (EQT)
      • 8.3.9.1. Participant's Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Vetoquinol S.A.
      • 8.3.10.1. Participant's Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 U.S. Companion Animal Health market, by animal type, 2018 - 2030 (USD Million)
  • Table 3 U.S. Companion Animal Health market, by product, 2018 - 2030 (USD Million)
  • Table 4 U.S. Companion Animal Health market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 5 U.S. Companion Animal Health market, by end use, 2018 - 2030 (USD Million)
  • Table 6 Participant's overview
  • Table 7 Financial performance
  • Table 8 Product benchmarking
  • Table 9 Strategic Initiatives

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Commodity Flow Analysis
  • Fig. 9 U.S. Companion Animal Health market revenue, 2018 - 2030 (USD Million)
  • Fig. 10 U.S. Companion Animal Health market snapshot
  • Fig. 11 U.S Companion Animal Health market driver impact
  • Fig. 12 U.S Companion Animal Health market restraint impact
  • Fig. 13 Porter's 5 Forces Analysis
  • Fig. 14 PESTEL Analysis
  • Fig. 15 U.S Companion Animal Health market animal type key takeaways (USD Million)
  • Fig. 16 U.S Companion Animal Health market: animal type movement analysis
  • Fig. 17 U.S dogs market, 2018 - 2030 (USD Million)
  • Fig. 18 U.S cats market, 2018 - 2030 (USD Million)
  • Fig. 19 U.S equine market, 2018 - 2030 (USD Million)
  • Fig. 20 U.S others market, 2018 - 2030 (USD Million)
  • Fig. 21 U.S Companion Animal Health product key takeaways (USD Million)
  • Fig. 22 U.S Companion Animal Health market: product movement analysis
  • Fig. 23 U.S biologics market, 2018 - 2030 (USD Million)
  • Fig. 24 U.S vaccines market, 2018 - 2030 (USD Million)
  • Fig. 25 U.S Modified/ Attenuated Live market, 2018 - 2030 (USD Million)
  • Fig. 26 U.S Inactivated (Killed) market, 2018 - 2030 (USD Million)
  • Fig. 27 U.S Other vaccines market, 2018 - 2030 (USD Million)
  • Fig. 28 U.S other biologics market, 2018 - 2030 (USD Million)
  • Fig. 29 U.S pharamceuticals market, 2018 - 2030 (USD Million)
  • Fig. 30 U.S parasiticides market, 2018 - 2030 (USD Million)
  • Fig. 31 U.S Anti-infectives market, 2018 - 2030 (USD Million)
  • Fig. 32 U.S Anti-inflammatory market, 2018 - 2030 (USD Million)
  • Fig. 33 U.S Analgesics market, 2018 - 2030 (USD Million)
  • Fig. 34 U.S supplements market, 2018 - 2030 (USD Million)
  • Fig. 35 U.S diagnostics market, 2018 - 2030 (USD Million)
  • Fig. 36 U.S others market, 2018 - 2030 (USD Million)
  • Fig. 37 U.S Companion Animal Health market distribution channel key takeaways (USD Million)
  • Fig. 38 U.S Companion Animal Health market: distribution channel movement analysis
  • Fig. 39 U.S retail market, 2018 - 2030 (USD Million)
  • Fig. 40 U.S e-commerce market, 2018 - 2030 (USD Million)
  • Fig. 41 U.S Hospital/ Clinic Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 42 U.S Companion Animal Health market end use key takeaways (USD Million)
  • Fig. 43 U.S Companion Animal Health market: end use movement analysis
  • Fig. 44 U.S Hospitals & Clinics market, 2018 - 2030 (USD Million)
  • Fig. 45 U.S Point-of-Care market, 2018 - 2030 (USD Million)
  • Fig. 46 U.S others market, 2018 - 2030 (USD Million)
  • Fig. 47 Market participant categorization
  • Fig. 48 Heat map analysis/Company market position analysis